Cyramza is a cancer medicine used to treat adult patients with: - gastric cancer (cancer of the stomach) or cancer of the area where the gullet (oesophagus) enters the stomach (known as gastro-oesophageal junction adenocarcinoma); - metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body); - non-small cell lung cancer that has spread to other parts of the body or in patients whose cancer involves mutations (changes) in proteins called endothelial growth factor receptors (EGFRs); - hepatocellular carcinoma (a type of liver cancer) in patients with a high blood level of a protein called alpha fetoprotein (AFP). Cyramza is for use in cancers that are usually advanced or have spread despite other treatment. For most cancers it is used in combination with other medicines. For detailed information on the use of Cyramza in all conditions, see the package leaflet or contact your doctor or pharmacist. Cyramza contains the active substance ramucirumab.
Therapeutic Indication
### Therapeutic indication **Gastric cancer** Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate. **Colorectal cancer** Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5?fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. **Non-small cell lung cancer** Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy. **Hepatocellular carcinoma** Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ? 400 ng/ml and who have been previously treated with sorafenib.
Therapeutic Area (MeSH)
ATC Code
L01FX06
ATC Item
dinutuximab beta
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Cyramza
Medicine Name
Cyramza
Aliases
N/ANo risk management plan link.
